Is Weakness In SMO ClinPlus CO.,LTD. (SZSE:301257) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Is Weakness In SMO ClinPlus CO.,LTD. (SZSE:301257) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
SMO ClinPlusLTD (SZSE:301257) has had a rough three months with its share price down 39%. But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Particularly, we will be paying attention to SMO ClinPlusLTD's ROE today.
SMO ClinPlusLtd(深圳證券交易所代碼:301257)經歷了艱難的三個月,其股價下跌了39%。但是,如果你密切關注,你可能會發現,鑑於市場通常會獎勵財務狀況良好的公司,其強勁的財務狀況可能意味着該股的長期價值可能會增加。特別是,我們今天將關注SMO ClinplusLtd的投資回報率。
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. Simply put, it is used to assess the profitability of a company in relation to its equity capital.
股本回報率或投資回報率是對公司增值和管理投資者資金的有效性的考驗。簡而言之,它用於評估公司相對於其股權資本的盈利能力。
See our latest analysis for SMO ClinPlusLTD
查看我們對 SMO ClinplusLtd 的最新分析
How Is ROE Calculated?
ROE 是如何計算的?
The formula for ROE is:
ROE 的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回報率 = 淨利潤(來自持續經營業務)÷ 股東權益
So, based on the above formula, the ROE for SMO ClinPlusLTD is:
因此,根據上述公式,SMO ClinplusLtd的投資回報率爲:
13% = CN¥135m ÷ CN¥1.0b (Based on the trailing twelve months to September 2023).
13% = 1.35億元人民幣 ÷ 1.0億元人民幣(基於截至2023年9月的過去十二個月)。
The 'return' is the amount earned after tax over the last twelve months. One way to conceptualize this is that for each CN¥1 of shareholders' capital it has, the company made CN¥0.13 in profit.
“申報表” 是過去十二個月的稅後收入金額。將其概念化的一種方法是,公司每擁有1元人民幣的股東資本,就能獲得0.13元人民幣的利潤。
What Is The Relationship Between ROE And Earnings Growth?
投資回報率與收益增長之間有什麼關係?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.
我們已經確定,投資回報率是衡量公司未來收益的有效盈利指標。根據公司選擇將多少利潤進行再投資或 “保留”,我們便能夠評估公司未來創造利潤的能力。假設其他條件都一樣,與功能不相同的公司相比,具有更高股本回報率和更高利潤保留率的公司通常具有更高的增長率。
SMO ClinPlusLTD's Earnings Growth And 13% ROE
SMO ClinPlusLtd 的收益增長和 13% 的投資回報率
To start with, SMO ClinPlusLTD's ROE looks acceptable. On comparing with the average industry ROE of 9.2% the company's ROE looks pretty remarkable. This probably laid the ground for SMO ClinPlusLTD's significant 25% net income growth seen over the past five years. We reckon that there could also be other factors at play here. For example, it is possible that the company's management has made some good strategic decisions, or that the company has a low payout ratio.
首先,SMO ClinplusLtd的投資回報率看起來可以接受。與9.2%的行業平均投資回報率相比,該公司的投資回報率看起來相當可觀。這可能爲SMO ClinplusLtd在過去五年中實現25%的顯著淨收入增長奠定了基礎。我們認爲,這裏可能還有其他因素在起作用。例如,公司的管理層可能做出了一些良好的戰略決策,或者公司的派息率很低。
As a next step, we compared SMO ClinPlusLTD's net income growth with the industry and found that the company has a similar growth figure when compared with the industry average growth rate of 27% in the same period.
下一步,我們將SMO ClinplusLtd的淨收入增長與該行業進行了比較,發現與同期27%的行業平均增長率相比,該公司的增長數字相似。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240201/0-ed8b08460f598175b04f4a3428bd48c4-0-27182bcdb8cc355e6b4eed72ab4578b3.png/big)
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. Doing so will help them establish if the stock's future looks promising or ominous. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if SMO ClinPlusLTD is trading on a high P/E or a low P/E, relative to its industry.
爲公司附加價值的基礎在很大程度上與其收益增長息息相關。無論情況如何,投資者都應設法確定預期的收益增長或下降是否已計入其中。這樣做將幫助他們確定股票的未來是樂觀還是不祥的。衡量預期收益增長的一個很好的指標是市盈率,它根據收益前景決定了市場願意爲股票支付的價格。因此,你可能需要檢查一下相對於其行業,SMO ClinplusLtd的交易市盈率是高還是低。
Is SMO ClinPlusLTD Using Its Retained Earnings Effectively?
SMO ClinplusLtd 是否在有效使用其留存收益?
SMO ClinPlusLTD has a really low three-year median payout ratio of 8.3%, meaning that it has the remaining 92% left over to reinvest into its business. So it seems like the management is reinvesting profits heavily to grow its business and this reflects in its earnings growth number.
SMO ClinPlusLtd的三年派息率中位數非常低,爲8.3%,這意味着它還有剩餘的92%可以再投資於其業務。因此,管理層似乎正在將利潤大量再投資以發展業務,這反映在其收益增長數字上。
While SMO ClinPlusLTD has been growing its earnings, it only recently started to pay dividends which likely means that the company decided to impress new and existing shareholders with a dividend.
儘管SMO ClinplusLtd的收益一直在增長,但它直到最近才開始派發股息,這可能意味着該公司決定用股息給新老股東留下深刻的印象。
Conclusion
結論
Overall, we are quite pleased with SMO ClinPlusLTD's performance. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. We also studied the latest analyst forecasts and found that the company's earnings growth is expected be similar to its current growth rate. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.
總體而言,我們對SMO ClinplusLtd的表現感到非常滿意。特別是,很高興看到該公司正在對其業務進行大量投資,再加上高回報率,這爲其收益帶來了可觀的增長。我們還研究了最新的分析師預測,發現該公司的收益增長預計與其當前的增長率相似。這些分析師的預期是基於對該行業的廣泛預期,還是基於公司的基本面?點擊此處進入我們分析師對公司的預測頁面。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。